The Cancer Research Center of Lyon has 22 research teams* organized in two scientific departments. The organizational chart presented below refers to the CRCL's project for it's evaluation by the HCERES prior to it's validation for the 2021-2025 period. 

*The 6 teams presented  at the bottom of the page are part of the CRCL until December 31st, 2020.

Tumor Escape, Resistance and Immunity

Directors : Julien MARIE / Pierre SAINTIGNY

GENERAL AIM OF THE DEPARTMENT

TERI department gathers the complementary expertise of research teams assessing the cellular and molecular mechanisms involved in tumor progression to propose novel therapeutic targets against cancer.

READ MORE

TERI DEPARTMENT IS COMPOSED OF 10 TEAMS

  • Apoptosis, cancer and development

Director Patrick Mehlen
MORE INFORMATION

  • Tumor immune surveillance and therapeutic targeting

Director Christophe Caux
MORE INFORMATION

  • Oncopharmacology

Co-directors Lars Peter Jordhiem / Charles Dumontet 
MORE INFORMATION

  • Cancer cell plasticity in melanoma

Co-directors Julie Caramel & Stéphane Dalle
MORE INFORMATION

  • Targeting non-canonical protein functions in cancer

Director Toufic Renno
MORE INFORMATION

  • Integrated analysis of the dynamics of cancer

Director Pierre Saintigny
MORE INFORMATION

  • TGF-beta and immuno-regulation

Director Julien C. Marie
MORE INFORMATION

  • Molecular regulation of cancer immunity

Director Yenkel Grinberg-Bleyer
MORE INFORMATION

  • Small molecules for biological targets

Director Isabelle Krimm
MORE INFORMATION

  • Adhesion and signaling in metastatic melanoma

Director Julien Ablain
MORE INFORMATION

Cancer Initiation and Tumor cell Identity

Directors : Véronique MAGUER-SATTA / Jean-Jacques DIAZ

GENERAL AIM OF THE DEPARTMENT

CITI department gathers the complementary expertise of research teams to explore the earliest transformation signals to favor early detection and prevent tumor progression. The CITI department teams decipher how tumors dynamic and microenvironment heterogeneity impact the fitness of the tumor, key issues to improve treatments efficiency.

READ MORE

CITI DEPARTMENT IS COMPOSED OF 12 TEAMS

  • Hepatitis viruses and pathobiology of chronic liver diseases

Director Fabien Zoulim
MORE INFORMATION

  • Epigenetic and epigenomics of hepatocellular carcinoma

Director Massimo Levrero
MORE INFORMATION

  • Senescence, cancer and aging

Director David Bernard
MORE INFORMATION

  • Cancer Cell Death

Director Gabriel Ichim
MORE INFORMATION

  • Inflammasome and cancer

Director Virginie Petrilli 
MORE INFORMATION

  • Ribosomes, translation and cancer

Director Jean-Jacques Diaz
MORE INFORMATION

  • BMP: ecosystem, stemness & dynamic in cancer

Director Véronique Maguer-Satta
MORE INFORMATION

  • Stemness in gliomas

Co-directors Mathieu Gabut / François Ducray
MORE INFORMATION

  • Cellular reprogramming, stem cells and oncogenesis

Director Fabrice Lavial
MORE INFORMATION

  • Genetics, epigenetics and biology of sarcoma

Director Franck Tirode
MORE INFORMATION

  • Signaling, metabolism and tumor progression

Director Germain Gillet
MORE INFORMATION

  • Cell death and childhood cancers

Co-directors Marie Castets & Jean-Yves Blay
MORE INFORMATION

CRCL teams until December, 31st, 2020

"Hepatocarcinogenesis and viral infection", Co-directors Isabelle Chemin & Philippe Merle

"Clinical and experimental models of lymphomagenesis", Co-directors Gilles Salle & Laurent Genestier

"Oestrogen signaling and breast tumor", Director Muriel Le Romancer

"Epigenetics and cancer", Director Peter Mulligan

"Development, cancer and stem cell", Director Michela Plateroti

"EMT and cancer cell plasticity", Director Alain Puisieux
CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :